<DOC>
	<DOCNO>NCT01169701</DOCNO>
	<brief_summary>The objective study compare cardiovascular profile everolimus mycophenolic acid immunosuppressive regimen calcineurin inhibitor mycophenolic acid regimen maintenance renal transplant patient</brief_summary>
	<brief_title>24 Months Follow-up , Two Arm Study Compare Cardiovascular Profile Regimen With Everolimus + Mycophenolic Acid ( MPA ) Versus ( vs. ) Regimen CNI+MPA Maintenance Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Received kidney transplant &gt; 6 month &lt; 3 year prior study enrollment Receiving immunosuppressive regimen include tacrolimus mycophenolic acid Between 18 70 year age Willing provide write informed consent Patients actual serum creatinine ≥ 2 mg/dl and/or eGFR≤ 40 ml/min and/or proteinuria≥ 500mg/day Patients suffer severe humoral and/or cellular rejection ( ≥ BANFF IIb , recurrent acute rejection steroid resistant acute rejection previous year Patients severe hypercholesterolemia ( &gt; 350 mg/dL ; &gt; 9 mmol/L ) hypertriglyceridemia ( &gt; 500 mg/dL ; &gt; 8.5 mmol/L ) . Patients control hyperlipidemia acceptable . Diabetic patient Woman childbearing potential planning become pregnant pregnant and/or lactate unwilling use effective mean contraception Presence psychiatric illness ( i.e. , schizophrenia , major depression ) , opinion site investigator , would interfere study requirement Any medical condition , opinion site investigator base recall chart review would interfere complete study Receiving investigational drug receive investigational drug within 30 day prior study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Renal transplant , everolimus , cardiovascular profile , CNI-free immunosuppression , leave ventricular hypertrophy , biopsy prove acute rejection ( BPAR )</keyword>
</DOC>